Hans Peter Hartung

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové

Publication